MRMD insider update: 138,888 RSUs vested; 40,764 shares withheld

Rhea-AI Filing Summary

MariMed (MRMD) reported an insider equity change by President and CEO Jon R. Levine. On 10/27/2025, 138,888 restricted stock units converted one-for-one into common shares. To cover taxes on the vesting, the issuer withheld 40,764 shares at a price of $0.1579 under a tax-withholding transaction.

After these transactions, Levine held 20,953,494 shares directly. In addition, 6,684,640 shares are held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children; Levine disclaims beneficial ownership of those securities. The RSUs were originally granted on October 27, 2022, and there are no unvested RSUs remaining under that grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levine Jon R

(Last) (First) (Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD, MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	10/27/2025		M		138,888	A	$0(1)	20,994,258	D
Common stock	10/27/2025		F		40,764(2)	D	$0.1579	20,953,494	D
Common stock								6,684,640	I	By the Jon Levine Family Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	10/27/2025		M			138,888	(4)	(4)	Common Stock, par value $.001 per share	138,888	$0	0	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.

3. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

4. These RSUs were granted on October 27, 2022; there are no unvested RSUs remaining under this RSU grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Remarks:

	/s/ Jon R. Levine	10/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MariMed (MRMD) disclose in this Form 4?

CEO Jon R. Levine had 138,888 RSUs convert into common stock on 10/27/2025, with 40,764 shares withheld for taxes at $0.1579.

How many MRMD shares does Jon R. Levine hold directly after the transaction?

He holds 20,953,494 shares directly following the reported transactions.

How many MRMD shares are held indirectly for Jon R. Levine?

There are 6,684,640 shares held indirectly by the Jon Levine Family Trust; he disclaims beneficial ownership.

What was the RSU-to-share conversion ratio for MRMD?

RSUs converted to common stock on a one-for-one basis.

Were any RSUs remaining unvested under the 10/27/2022 grant?

No. The filing states there are no unvested RSUs remaining under that grant.

What roles does Jon R. Levine hold at MariMed (MRMD)?

He is a Director, President and CEO, and a 10% Owner.